Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy protection promises.
In its announcement of the acquisition, Regeneron assured 23andMe’s 15 million customers that their data—including genetic and health information, genealogy, and other sensitive personal information—would be safe and in good hands. Regeneron aims to use the large trove of genetic data to further its own work using genetics to develop medical advances—something 23andMe tried and failed to do.
“As a world leader in human genetics, Regeneron Genetics Center is committed to and has a proven track record of safeguarding the
→ Continue reading at Ars Technica